Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health and participating components, led by the National Institute of Allergy and Infectious Diseases and the Office of AIDS Research, are offering funding to support implementation research on HIV prevention, treatment, and care. Funded projects must focus on strategies to improve the uptake, sustainment, scale, and spread of evidence-based interventions in U.S. communities significantly impacted by HIV. Research must be grounded in implementation science frameworks, incorporate meaningful community engagement, and focus exclusively on domestic populations, as foreign organizations and foreign subawards are ineligible. This opportunity utilizes the R61/R33 Exploratory/Developmental Phased Award mechanism, which provides up to two years and $750,000 in annual direct costs for the R61 planning phase before transitioning to a multi-year R33 implementation phase. Total combined funding of approximately $48.5 million is anticipated in fiscal year 2027 to support dozens of awards, and applications may be submitted starting October 10, 2026, through the final closing date of June 20, 2029.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).